ASX Announcement
29 June 2022

OncoSil PanCO Clinical Trial Presented at ESMO World Congress on Gastrointestinal Cancer (WCGIC) focusing on resected and non-resected participant data

Sydney, Australia, 29 June 2022: OncoSil Medical Limited (ASX: OSL) (**OncoSil** or the **Company**) is pleased to announce that the Principal Investigator of the PanCO study will be presenting both an oral and poster presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) on 29 June 2022. The presentation is titled "**Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study**". The presentation focuses upon data in the resected and non-resected participants in the PanCO Study. The presenter is Dr Paul Ross, Consultant Medical Oncologist from Guy's & St Thomas' Hospital NHS Foundation Trust, London and Principal Investigator of the PanCO study. The presentation and poster can be viewed after 2 July 2022 at https://www.oncosil.com/news/.

OncoSil's CEO and Managing Director, Mr Nigel Lange said:

"We are delighted to be able to present additional data from our PanCO Study, comparing the baseline characteristics and outcomes in the participants who went on to have surgical resection compared to those who did not. This new analysis shows that the resected participants had a substantial response to treatment before they underwent surgery. These clinical findings have motivated increased interest from Hepato-Pancreatico-Billary (HPB) surgeons who have been encouraged by the reduction in tumour volumes following treatment. Reduction of tumour volume may increase the potential for surgical resection and may be linked with the encouraging survival of the resected cohort of patients being administered the OncoSil™ device."

About WCGIC:

The ESMO World Congress on Gastrointestinal Cancer represents the year's premier gathering of international oncology professionals who are dedicated to improving the lives of patients impacted by diseases of the GI tract. The Congress is the leading global platform for discussing the latest emerging data and new research in this rapidly advancing scientific field. It is being held on 29 June 2022 to 2 July 2022 in Barcelona, Spain.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com

Company	Company
Mr Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr Karl Pechmann CFO & Company Secretary E: karl.pechmann@oncosil.com T: +61 2 9223 3344

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable intrahepatic and distal cholangiocarcinoma. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $3b.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.